双歧杆菌三联活菌胶囊治疗非酒精性脂肪肝的效果分析

作者单位:117000 辽宁 本溪,辽宁省健康产业集团本钢总医院消化内科

 非酒精性脂肪肝;药物治疗;双歧杆菌三联活菌;肝功能;血脂

Effect of Bifidobacterium Triple Viable Capsule in the Treatment of Non-alcoholic Fatty Liver Disease
MA Ruihong, HUANG Yingqiu

(Department of Gastroenterology, General Hospital of Benxi Iron Company of Liaoning Province, Liaoning Health Industry Group, Benxi 117000, Liaoning Province, China)

 Non-alcoholic Fatty Liver Disease; Medication; Bifidobacterium Triple Viable Capsule; Liver Function; Blood Lipid

DOI: 10.3969/j.issn.1672-7185.2019.11.022

备注

 目的  探讨双歧杆菌三联活菌胶囊治疗非酒精性脂肪肝的效果。方法  选取辽宁省健康产业集团本钢总医院2017年1月—2018年12月收治的120例非酒精性脂肪肝患者,随机分为观察组和对照组各60例,对照组采用非药物干预联合保肝治疗,在对照组治疗基础上观察组加用双歧杆菌三联活菌胶囊,比较两组的治疗效果。结果  观察组治疗总有效率86.67%(52/60),高于对照组的68.33%(41/60),差异有统计学意义( χ2=5.783, P<0.05)。治疗后两组血脂和肝功能各项指标均得到改善,且治疗后观察组血脂水平及肝功能各项指标优于对照组,差异有统计学意义(P<0.05)。对照组不良反应发生率6.67%(4/60),低于观察组的10.00%(6/60),但两组差异无统计学意义(χ2=0.436,P>0.05)。结论  非酒精性脂肪肝患者采用双歧杆菌三联活菌胶囊治疗可提高疗效,改善肝功能和血脂水平,且不会增加不良反应发生,值得临床推广使用。
Objective To explore the effect of bifidobacterium triple viable capsule in the treatment of non­alcoholic fatty liver. Methods  A total of 120 cases of non-alcoholic fatty liver patients admitted to Bengang General Hospital of Liaoning Health Industry Group from January 2017 to December 2018 were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with non-drug intervention combined with hepatoprotective therapy, and the observation group was treated with bifidobacterium triple viable capsule on the basis of the control group. The therapeutic effects of the two groups were compared. Results  The total effective rate of the observation group was 86.67%(52/60), higher than 68.33%(41/60) of the control group(χ2=5.783, P<0.05). After treatment, the indexes of blood lipid and liver function in the two groups were improved, and the indexes of blood lipid and liver function in the observation group were significantly better than those in the control group(P<0.05). The incidence of adverse reactions in the control group was 6.67%(4/60), lower than that in the observation group 10.00%(6/60), but there was no significant difference between the two groups(χ2=0.436, P>0.05). Conclusion  The bifidobacterium triple viable capsule can improve the curative effect, liver function and blood lipid level, and will not increase the incidence of adverse reactions in the treatment of non­alcoholic fatty liver, which is worthy of clinical application.